Free press releases distribution network?

Agency / Source: Foamix Ltd

Check Ads Availability|e-mail Article
This article was published free of charge. Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!



Foamix to Present at the UBS 2010 Global Specialty Pharmaceuticals Conference - The Company will discuss its strategic partnerships and innovative in-house pipeline, including first-in-class Topical Minocycline
Foamix to Present at the UBS 2010 Global Specialty Pharmaceuticals Conference

 

PRTODAY - Newswire & PRZOOM/ - Rehovot, Israel, 06/02/2010 - The Company will discuss its strategic partnerships and innovative in-house pipeline, including first-in-class Topical Minocycline.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Foamix Ltd., will present at the UBS 2010 Global Specialty Pharmaceuticals Conference, which will be held from June 2-3 in London, UK.

Dov Tamarkin, Ph.D., Foamix's CEO, will speak on Thursday June 3, 2010 at 9:30 pm London time. He will provide an overview of the company, its technologies and strategic partnerships with pharmaceutical companies. He will further provide an update on Foamix’s innovative drug development pipeline, which includes the first-in-class Topical Minocycline, as well as other proprietary products. Foamix’s Topical Minocycline is currently in Phase II clinical trials in a number of dermatological conditions, with a projected launch in 2013-14.
The Company’s Topical Minocycline will also be developed for a number of ophthalmic and women’s health applications, through partnerships with leading companies in these fields.

About UBS
Headquartered in Zurich and Basel, Switzerland, UBS is a client-focused financial services firm that offers a combination of wealth management, asset management and investment banking services on a global and regional basis. By delivering a full range of advice, products and services to its private, corporate and institutional clients, UBS aims to generate sustainable earnings, create value for its shareholders, and become the choice of clients worldwide.
The UBS 2010 Global Specialty Pharmaceuticals Conference will take place from Wednesday, 2 - Thursday, 3 June 2010 at the UBS Offices, 1 Finsbury Avenue, London EC2M 2PP.

About Foamix Ltd
Headquartered in Rehovot, Israel, Foamix Ltd. (foamix.co.il) is a clinical-stage, privately held specialty pharmaceutical company, focused on the development of proprietary topical foam and OilGel™ products for prescription, OTC and cosmetic applications. By incorporating drugs in foam and OilGel™, Foamix creates advanced, patent protected products with improved convenience, higher compliance and better efficacy. The company’s development capabilities range from initial development of the formulations to scale-up, GMP manufacturing, preclinical and clinical studies.
Foamix partners with leading pharmaceutical companies, including Galderma, Bayer, Dr. Reddy's and Ferndale Laboratories.
Foamix further has its own in-house pipeline of dermatological and gynecological drugs. The Company’s lead product, Topical Minocycline, is in clinical development for the treatment of rosacea, acne and skin infections; Topical Minocycline has further applications in the fields of ophthalmic therapy and gynecology.

To date, Foamix has twenty three issued patents worldwide covering its foam and OilGel™ technology platforms, including 8 issued patents in the United States. The company has an additional 150 pending patent applications worldwide, of which more than 50 are filed in the U.S.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Agency / Source: Foamix Ltd

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick PRTODAY - Newswire Distribution Service Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Foamix to Present at the UBS 2010 Global Specialty Pharmaceuticals Conference

Non-featured company website links are shown on a random basis
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name PRTODAY - Newswire Distribution Service and LINK as the source.
 
  For more information, please visit:
Links are available on a random basis for non premium members
|
Contact: Dov Tamarkin - Foamix.co.il 
+972 8 9316233 dov[.]foamix.co.il
 
Newswire Today - PRZOOM disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.

Pharma/BioTech/Nutrition via RSS
AddThis press release: Foamix to Present at the UBS 2010 Global Specialty Pharmaceuticals ConferenceAdd Pharma/BioTech/Nutrition News to My MSNAdd Pharma/BioTech/Nutrition News to My Yahoo!Add NewswireToday Pharma/BioTech/Nutrition Press Release Headline News to Your Google homepage or Google ReaderAdd NewswireToday - PRZOOM Headline News to FeedBurner

This article was published free of charge. Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!




Read More Articles From Foamix Ltd / Company Profile



Read Pharma/BioTech/Nutrition Most Recent Related Press Releases:

Genentech to Present New Data at AAN Highlighting Extensive Research for Ocrevus and Expanding Neuroscience Pipeline
Sartorius Stedim Biotech and Penn State University Announce Partnership
SIO and BTG Announce Recipients of Immuno-Oncology/Interventional Oncology Grant Program
Ipsen Receives Positive CHMP Opinion for Cabometyx® (cabozantinib) for the First-line Treatment of Adults with Intermediate or Poor Risk aRCC
FDA Approves Genentech’s Lucentis (Ranibizumab Injection) 0.3 mg Prefilled Syringe for Diabetic Macular Edema and Diabetic Retinopathy
Sartorius Stedim Biotech Supports ABL Europe in Successful Completion of Viral Vector GMP Capacity Expansion
BASF Launches Hepaxa as First Dedicated Product in the U.S. to Help Patients Manage Non-Alcoholic Fatty Liver Disease
Legend Biotech Announces Closing of Global Strategic LCAR-B38M Car-T Cell Immunotherapy Collaboration with Janssen
Arix Bioscience and Ipsen Sign A Strategic Agreement to Develop and Commercialise Innovative Therapies
Ipsen Announces Eight Oral Presentations from its Neurosciences Portfolio At the 10th World Congress for Neurorehabilitation (WCNR)

Reserve This Permanent SPACE

Your LOGO permanently HERE on PRTODAY - Newswire Distribution Service most visited Page start at $295 per month

 
Sponsored Links


Visit Reverie Language Technologies (P) Ltd

Visit  La Bella Bakery Artisan Bakery Arizona

Visit  E-MetroTel Global, Inc.





Find business coaching, life coaching, executive coaching and corporate coaching, best selling coaching books, ...



 
  ©2014 PRTODAY — Limelon Advertising, Co.
Home | About PRTODAY | Advertise | Contact | Investors | Sitemap | FRANCAIS
newswire, PR free press releases distribution magazines engine news alert newsroom press room breaking news public relations articles company news alerts blogsIt younews.me newswiredistribution ezine younews.asia bizentrepreneur biznewstoday digital business report news market search pr firms pr agencies business reports newswire today distri- bution investor relation successful internet entrepreneur free newswire distribution prtoday freenewswiredistribution.com asianewstoday bizwiretoday newswire pr today
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)